Evaluates futibatinib's effectiveness for FGFR2-altered cholangiocarcinoma, suggesting a breakthrough in treatment options.
Futibatinib represents the most biologically rational FGFR inhibitor currently available for FGFR2-altered CCA, as it directly addresses the dominant mechanism limiting the efficacy of earlier agent, on-target resistance driven by secondary FGFR2 kinase domain mutations.
No takes yet. Share an insight, caveat, or question.
Persano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: